Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telmisartan - Boehringer Ingelheim/GlaxoSmithKline

Drug Profile

Telmisartan - Boehringer Ingelheim/GlaxoSmithKline

Alternative Names: BIBR277; Kinzal; Kinzalmono; Micardis; Pritor; PritorPlus; Telma; YM086

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Abbott Laboratories; Astellas Pharma; Boehringer Ingelheim Pharma KG; GlaxoSmithKline; Glenmark Pharmaceuticals Ltd; Nippon Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Essential hypertension; Hypertension
  • No development reported Metabolic syndrome
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Oct 2017 Nippon Boehringer Ingelheim and Astellas Pharma extend agreement related to the sales of telmisartan (Micardis® family) in Japan
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan (Micardis® family) in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top